Revolution Medicines has been granted a patent for macrocyclic compounds that inhibit Ras proteins, potentially offering a new treatment for cancers. The compounds and their pharmaceutical compositions are designed to target specific proteins involved in cancer growth. GlobalData’s report on Revolution Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Revolution Medicines, Cancer treatment biomarkers was a key innovation area identified from patents. Revolution Medicines's grant share as of April 2024 was 13%. Grant share is based on the ratio of number of grants to total number of patents.
Inhibiting ras proteins for cancer treatment
A recently granted patent (Publication Number: US11952352B2) discloses a series of claims related to compounds and pharmaceutical compositions. The patent claims include the chemical structures of specific compounds, as well as pharmaceutical compositions containing these compounds. The compounds and compositions described in the patent are intended for use in various applications, potentially offering new solutions in the field of pharmaceutical research and development.
The patent claims cover the structural formulas of the compounds and pharmaceutical compositions, indicating a specific focus on the chemical makeup and potential therapeutic properties of the disclosed substances. By securing this patent, the inventors have established exclusive rights to these specific compounds and compositions, potentially paving the way for further research, development, and commercialization in the pharmaceutical industry. The granted patent provides a foundation for future innovation and exploration in the field of pharmaceuticals, offering a glimpse into the potential advancements that may arise from the utilization of the disclosed compounds and compositions.
To know more about GlobalData’s detailed insights on Revolution Medicines, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
